USS Investment Management’s Neurocrine Biosciences NBIX Stock Holding History

USS Investment Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-7,018	Closed	-$684K	–	665
2022 Q2	$684K	Sell	7,018 -1,368	-16%	-$126K	0.01%	643
2022 Q1	$787K	Sell	8,386 -12,361	-60%	-$1.05M	0.01%	672
2021 Q4	$1.77M	Hold	20,747	–	–	0.01%	648
2021 Q3	$1.99M	Buy	20,747 +15,312	+282%	+$1.45M	0.02%	627
2021 Q2	$529K	Hold	5,435	–	–	﹤0.01%	584
2021 Q1	$529K	Hold	5,435	–	–	﹤0.01%	572
2020 Q4	$521K	Hold	5,435	–	–	﹤0.01%	562
2020 Q3	$523K	Hold	5,435	–	–	0.01%	545
2020 Q2	$663K	Buy	+5,435	New	+$601K	0.01%	517

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

USS Investment Management's NBIX Position: Q3 2022 in Review

USS Investment Management sold out of Neurocrine Biosciences (NBIX) in Q3 2022, closing a stake of 7,018 shares — an estimated $684K sold.

USS Investment Management first reported a position in NBIX in Q2 2020 and held it in 9 quarters. The position peaked at $1.99M in Q3 2021. 466 funds tracked by Wall St. Rank hold NBIX as of Q3 2022.

USS Investment Management reported no remaining Neurocrine Biosciences position as of Q3 2022 after selling out during the quarter.
USS Investment Management sold 7,018 Neurocrine Biosciences shares in Q3 2022, an estimated $684K.
USS Investment Management first reported a position in Neurocrine Biosciences in Q2 2020 and held it in 9 quarters.
USS Investment Management's Neurocrine Biosciences position peaked at $1.99M in Q3 2021.
466 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2022.

Based on USS Investment Management's 13F filing for Q3 2022, filed 8 Nov 2022.